Skip to main content
SpringerLink
Log in

Ocular allergy: avoidance of allergens and symptomatic therapy still the mainstay of treatment for most patients

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure

References

  1. Bielory L. Ocular allergy guidelines: a practical treatment algorithm. Drugs 2002; 62(11): 1611–34

    Article  PubMed  CAS  Google Scholar 

  2. Hingorani M, Lightman S. Therapeutic options in ocular allergic disease. Drugs 1995 Aug; 50(2): 208–21

    Article  PubMed  CAS  Google Scholar 

  3. Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol 1994; 94(1): 134–6

    Article  PubMed  CAS  Google Scholar 

  4. Alexander M, Rosen LJ, Young WH. Comparison of topical nedocromil sodium and oral terfenadine for the treatment of seasonal allergic conjunctivitis. Clin Ther 1999; 21(11): 1900–7

    Article  PubMed  CAS  Google Scholar 

  5. British National Formulary. No. 44 [online]. Available from URL: http://www.bnf.org [Accessed 2003 Feb 28]

  6. Arriaga F, Rombaut N. Absence of central effects with levocabastine eye drops. Allergy 1990; 45(7): 552–4

    Article  PubMed  CAS  Google Scholar 

  7. Secchi A, Leonardi A, Discepola M, et al. An efficacy and tolerance comparison of emedastine difumerate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group. Acta Ophthalmol Scand Suppl 2000 Jun; (230): 48–51

  8. Abelson MB, Paradis A, George MA, et al. Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis. Arch Ophthalmol 1990; 108(4): 520–4

    Article  PubMed  CAS  Google Scholar 

  9. Santos CI, Huang AJ, Abelson MB, et al. Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. Am J Ophthalmol 1994 Apr 15; 117(4): 488–97

    PubMed  CAS  Google Scholar 

  10. Yanni JM, Miller ST, Gamache DA, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol 1997 Dec; 79(6): 541–5

    Article  PubMed  CAS  Google Scholar 

  11. Gonzalez JP, Brodgen RN. Nedocromil sodium: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease. Drugs 1987; 34(5): 456–77

    Article  Google Scholar 

  12. Ballas Z, Blumenthal M, Tinkelman DG, et al. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993 Jul–Aug; 38 Suppl.: 141–8

  13. Sharma A, Gupta R, Ram J, et al. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Opthalmol 1997 Sep; 45(3): 177–80

    CAS  Google Scholar 

  14. Sitenga GL, Ing EB, Van Dellen RG, et al. Asthma caused by topical application of ketorolac. Opthalmology 1996 Jun; 103(6): 890–2

    CAS  Google Scholar 

  15. Donshik PC, Pearlman D, Pinnas J, et al. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis. Adv Ther 2000 Mar–Apr; 17(2): 94–102

    Google Scholar 

  16. Winther L, Malling HJ, Moseholm L, et al. Allergen-specific immunotherapy in birch-and grass-pollen-allergic rhinitis: I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts. Allergy 2000 Sep; 55(9): 818–26

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ocular allergy: avoidance of allergens and symptomatic therapy still the mainstay of treatment for most patients. Drugs Ther. Perspect 19, 13–16 (2003). https://doi.org/10.2165/00042310-200319070-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319070-00005

Keywords

Search

Navigation